Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response.

ABSTRACT: While most ovarian cancer (OC) patients respond to front-line platinum/taxane chemotherapy and surgical debulking, the majority will develop platinum-resistance and recur. Our study investigated how tumor-associated macrophages (TAMs) within the tumor microenvironment (TME) affect chemotherapy outcomes using OC patient-derived organoids and humanized patient-derived xenografts (huPDX). In vitro macrophage migration assays demonstrated the selective recruitment of M2 macrophages to organoids. M2 macrophages, but not M1, increase organoid viability and reduce their sensitivity to paclitaxel in co-culture assays. Furthermore, BMS777607, a receptor tyrosine kinase inhibitor capable of repolarizing M2 macrophages in vitro, reduced organoid viability via a macrophage-dependent mech

SUBMITTER: Nikeghbal P 

PROVIDER: S-EPMC12320822 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature